Results 211 to 220 of about 58,361 (283)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism. [PDF]

BMC Endocr Disord
Thipbumrung S, Manosroi W.
europepmc   +1 more source

Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist. [PDF]

Cureus
Ramadan MM, Alajmi S, Aldouseri J, Alajmi M, Tello EA, Mahdi AO, Aladwani AJ, Alayyaf AE, Mahdi O, Elmahal M.   +9 more
europepmc   +1 more source

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases. [PDF]

ESC Heart Fail
Wang J, Zheng M, Yang Y, Zhang L, Wulasihan M.   +4 more
europepmc   +1 more source

Mineralocorticoid receptor knockout alters hippocampal CA2 neurons to become like those in CA1. [PDF]

Commun Biol
Harris EP, Kandemir B, Jones SM, Alexander GM, Ward JM, Wang T, Proaño S, Xu X, Dudek SM.   +8 more
europepmc   +1 more source

Clinical implications of mineralocorticoid receptor overactivation. [PDF]

Clin Kidney J
El Mouhayyar C, Chhikara M, Tang M, Nigwekar SU.   +3 more
europepmc   +1 more source

Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia. [PDF]

Am Heart J Plus
Hassen M, Worku BT, Solomon T, Demessie MB, Wendie TF, Muhammed OS, Gobezie MY.   +6 more
europepmc   +1 more source

Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Muhammad Daniyal S, Ajaz H, Riaz M, Murad Khatoon N, Aftab Z, Tauqir Gondal H, Gul I, Sarwar M, Batool F, Fahim SL, Noor A, Khalid A, Ashraf DA, Jabarkhil R.   +13 more
europepmc   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Kobayashi M, Duarte K, Ferreira JP, Baudry G, Monzo L, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F, Girerd N.   +9 more
europepmc   +1 more source

Mineralocorticoid receptor antagonism for non-diabetic kidney disease. [PDF]

Nephrol Dial Transplant
Jaisser F, Barrera-Chimal J.
europepmc   +1 more source

Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors? [PDF]

Eur Heart J Cardiovasc Pharmacother
Komiyama M, Hasegawa K, Rosano GMC.
europepmc   +1 more source